ESTABLISHEDSCIENCEscience-backed 100%
Geriatric Illness And Health Studies
Quality 82/100185 signals4 source typessince 2025-06-22
What is this
This trend focuses on studies addressing illnesses predominantly affecting the elderly, from physiological responses to novel dietary interventions. It integrates clinical trials and multidisciplinary research to better understand geriatric health challenges.
Why it matters
The global demographic shift toward an aging population makes understanding and addressing elderly health issues increasingly urgent. Rising healthcare costs and the burden on social systems act as key catalysts for innovation in geriatric research.
Investment angle
Investors can target healthcare companies focusing on elder care, pharmaceuticals tailored to geriatric conditions, and tech startups offering digital health solutions for seniors. Additionally, specialized healthcare ETFs and long-term investments in medical research organizations may provide steady returns.
Sovenyr read
A solid long-term opportunity with stable growth, ideal for conservative portfolios seeking healthcare exposure. Investability: 7/10.
History
Flagged 2025-06-22 · Status ESTABLISHED (since 2026-03-15) · last active 2026-07-28
2026-03-08signals (cumulative): 3 → 1852026-07-28
Y = cumulative signals, X = time. A steep climb means the cluster is actively growing; a flat or abruptly-ending line means momentum is gone.
| date | signals | new | substance |
|---|---|---|---|
| 2026-03-08 | 3 | 100% | |
| 2026-03-19 | 45 | +42 | 100% |
| 2026-03-29 | 46 | +1 | 100% |
| 2026-04-10 | 47 | +1 | 100% |
| 2026-04-21 | 52 | +5 | 100% |
| 2026-05-01 | 161 | +109 | 100% |
| 2026-05-14 | 165 | +4 | 100% |
| 2026-05-25 | 166 | +1 | 100% |
| 2026-06-05 | 170 | +4 | 100% |
| 2026-06-15 | 171 | +1 | 100% |
| 2026-06-26 | 175 | +4 | 100% |
| 2026-07-07 | 177 | +2 | 100% |
| 2026-07-17 | 181 | +4 | 100% |
| 2026-07-28 | 185 | +4 | 100% |
Evidence
The 185 collected signals behind this trend — the 20 most recent, each linking to its primary source.
- 2026-07-27ClinicalTrials.gov[PHASE4] A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity · detail
- 2026-07-27ClinicalTrials.gov[NA] Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy · detail
- 2026-07-24ClinicalTrials.gov[PHASE2] A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity · detail
- 2026-07-20ClinicalTrials.gov[NA] Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide · detail
- 2026-07-17ClinicalTrials.gov[NA] A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control · detail
- 2026-07-14ClinicalTrials.gov[] Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists · detail
- 2026-07-10ClinicalTrials.gov[] Imaging in Semaglutide Study · detail
- 2026-07-09ClinicalTrials.gov[PHASE1] Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents · detail
- 2026-07-06ClinicalTrials.gov[PHASE2] Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes · detail
- 2026-06-29EPO Patents[EPO] METHODS OF TREATING INSULIN RESISTANCE AND ASSOCIATED DISORDERS · detail
- 2026-06-25ClinicalTrials.gov[PHASE2] A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes · detail
- 2026-06-25ClinicalTrials.gov[PHASE3] A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide · detail
- 2026-06-23ClinicalTrials.gov[PHASE3] A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting · detail
- 2026-06-23ClinicalTrials.gov[PHASE3] A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus · detail
- 2026-06-05ClinicalTrials.gov[PHASE3] BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes · detail
- 2026-06-04ClinicalTrials.gov[] Weight Loss in Adults Using Semaglutide (Real-world Study) · detail
- 2026-06-03ClinicalTrials.gov[PHASE3] BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity · detail
- 2026-06-02ClinicalTrials.gov[] Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin · detail
- 2026-05-26ClinicalTrials.gov[PHASE1] Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events · detail
- 2026-05-19ClinicalTrials.gov[PHASE1] A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity · detail